Danish pharmaceutical company ALK has secured exclusive global rights to ARS Pharmaceuticals’ Neffy nasal spray, except in select markets, for the treatment of allergic reactions, including anaphylaxis. The deal, valued at over $465 million, positions ALK for significant growth in the anaphylaxis market, with Neffy poised to become a key player in Europe and Canada.
The FDA has approved FluMist, a nasal spray flu vaccine, for at-home use, offering a convenient and accessible option for individuals ages 18 to 49. This approval expands on the existing use of FluMist for children and adolescents ages 2 to 17, allowing their caregivers to administer the spray. The move comes after clinical trials demonstrated the safety and effectiveness of self-administering the vaccine, making flu protection more accessible for a wider population.
This article shares the author’s experience battling a cold with the help of products from Holland & Barrett. It features a detailed breakdown of Manuka honey, Vitamin C, nasal sprays, Vitamin B supplements, and lozenges, highlighting their benefits and how they helped alleviate cold symptoms.
